Literature DB >> 1430813

[Ocular prognosis in Behçet's disease].

I Cochereau-Massin1, B Wechsler, P Le Hoang, D u Le Thi Huong, B Girard, F Rousselie, P Godeau.   

Abstract

The ocular prognosis of Behçet's disease was assessed in 31 French native patients with ocular involvement. The mean follow-up time was 6 years. Ophthalmologic manifestations revealed the disease in 61% of patients, and it was the first symptom in 29%. Two groups of patients could be identified: the minor forms (23%) which remained stable with colchicine alone and the severe forms (77%) which required steroid (32%) and/or immunosuppressive (45%) therapy. In the severe forms, 32 eyes were unchanged, 4 eyes showed improvement, and 12 eyes showed deterioration in visual acuity. Positivity of HLA B5, sex and complete form of the disease were not predictive factors of ocular involvement, or of its seriousness. At 6 years, 16% of the eyes (versus 14% at the beginning) had a visual acuity less than 1/10, and 71% (versus 74% at the beginning) had a visual acuity greater than 8/10. A close collaboration between ophthalmologists and internists allows a good visual prognosis in Behçet's disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1430813

Source DB:  PubMed          Journal:  J Fr Ophtalmol        ISSN: 0181-5512            Impact factor:   0.818


  8 in total

1.  Primary association of HLA-B51 with Behçet's disease in Ireland.

Authors:  D J Kilmartin; A Finch; R W Acheson
Journal:  Br J Ophthalmol       Date:  1997-08       Impact factor: 4.638

Review 2.  Outcome measures used in clinical trials for Behçet syndrome: a systematic review.

Authors:  Gulen Hatemi; Peter A Merkel; Vedat Hamuryudan; Maarten Boers; Haner Direskeneli; Sibel Z Aydin; Hasan Yazici
Journal:  J Rheumatol       Date:  2014-02-01       Impact factor: 4.666

3.  Causes and frequency of blindness in patients with intraocular inflammatory disease.

Authors:  A Rothova; M S Suttorp-van Schulten; W Frits Treffers; A Kijlstra
Journal:  Br J Ophthalmol       Date:  1996-04       Impact factor: 4.638

4.  [Typical and atypical ocular manifestations of Behçet's disease].

Authors:  N Stübiger; U Pleyer
Journal:  Ophthalmologe       Date:  2012-06       Impact factor: 1.059

5.  Human recombinant interferon alfa-2a for the treatment of Behçet's disease with sight threatening posterior or panuveitis.

Authors:  I Kötter; M Zierhut; A K Eckstein; R Vonthein; T Ness; I Günaydin; B Grimbacher; S Blaschke; W Meyer-Riemann; H H Peter; N Stübiger
Journal:  Br J Ophthalmol       Date:  2003-04       Impact factor: 4.638

6.  Treatment of ocular symptoms of Behçet's disease with interferon alpha 2a: a pilot study.

Authors:  I Kötter; A K Eckstein; N Stübiger; M Zierhut
Journal:  Br J Ophthalmol       Date:  1998-05       Impact factor: 4.638

7.  Behçet's disease in black skin. A retrospective study of 50 cases in Dakar.

Authors:  Maodo Ndiaye; Aboubacary Sadikh Sow; Abbaspour Valiollah; Moussa Diallo; Assane Diop; Rachidi Amal Alaoui; Boubacar Ahy Diatta; Fatimata Ly; Suzanne Oumou Niang; Mame Thierno Dieng; Assane Kane
Journal:  J Dermatol Case Rep       Date:  2015-12-31

8.  [Ophthalmologic manifestations of Behçet's disease, about 33 cases].

Authors:  Idriss Benatiya Andaloussi; Bouchra Alami; Meryem Abdellaoui; Salima Bhallil; Wafae Bono; Hicham Tahri
Journal:  Pan Afr Med J       Date:  2012-12-19
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.